Compounded Tirzepatide: Legal Status, FDA Rules, and Safety Risks in 2026

Compounded tirzepatide is tirzepatide mixed by a pharmacy instead of made by the drug's manufacturer, and it is not FDA approved. Mass copies were allowed only during the national tirzepatide shortage, which FDA declared over in October 2024 and again in December 2024. As of September 24, 2026, only narrow compounding for individual patients remains.

The only FDA-approved tirzepatide medicines are Zepbound and Mounjaro. Their safety data come from large clinical trials, summarized in our page on Zepbound side effects. We found no published clinical trials of compounded tirzepatide products.

In this guide you will learn:

• What compounded tirzepatide is and how it differs from Zepbound and Mounjaro
• Whether it is legal in 2026, for pharmacies and for outsourcing facilities
• The timeline: shortage, court case, and the 2026 FDA crackdown
• What FDA adverse event reports and new studies show about safety
• How to check that a compounding pharmacy is licensed

This page explains the law and the risks. It does not name sellers, give prices, or give doses.

Table of Contents

• What is compounded tirzepatide?
• Is compounded tirzepatide legal in 2026?
• Compounded tirzepatide timeline: shortage, court case, and 2026 crackdown
• Compounded tirzepatide vs Zepbound and Mounjaro
• Is compounded tirzepatide safe? What FDA reports show
• How to check that a compounding pharmacy is licensed
• If you use compounded tirzepatide now: questions for your prescriber
• Eating well on any tirzepatide treatment
• Key takeaways
• Frequently asked questions

What Is Compounded Tirzepatide?

Compounded tirzepatide is a version of tirzepatide that a pharmacy or outsourcing facility prepares itself, and its form, strength, and added ingredients vary between compounders. FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients [1][2].

It is also not a generic. In March 2026, FDA stated that compounded drugs "are also not the same as generic drugs, which are FDA-approved" [5]. FDA's drug database lists only two tirzepatide applications, both from Eli Lilly: Mounjaro, approved in May 2022, and Zepbound, approved in November 2023 [9][19]. For every FDA-approved option, see our GLP-1 medications list.

Compounding itself has a real medical role. FDA's guidance gives the example of a prescription that reads "No Dye X, patient allergy" [10]. FDA's consumer advice is that compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug" [2].

Two kinds of compounders exist under federal law [11][12]:

• 503A pharmacies. State-licensed pharmacies that compound for individual patients with a prescription. State boards of pharmacy handle their day-to-day oversight.
• 503B outsourcing facilities. Facilities registered with FDA. FDA inspects them on a risk-based schedule, and they must follow current good manufacturing practice (CGMP) rules and report adverse events to FDA.

Is Compounded Tirzepatide Legal in 2026?

Compounded tirzepatide is legal only in narrow cases as of September 24, 2026. A state-licensed pharmacy may compound it for an individual patient with a prescription, but not as a routine copy of Zepbound or Mounjaro. Outsourcing facilities cannot compound it from bulk ingredients [1].

The reason is the end of the shortage. On October 2, 2024, FDA explained that "when a drug shortage is resolved, FDA generally considers the drug to be commercially available" [1]. Copies of a commercially available drug then fall under strict limits again.

Sources: FDA compounding policy update (current as of 04/01/2026), FDA Compounding Q&A, FDA concerns page (current as of 09/01/2026), Federal Register.

What "Personalized" Compounding Means Under FDA Rules

Many sellers describe compounded tirzepatide as "personalized," but FDA uses a specific test. FDA's January 2018 guidance for 503A pharmacies defines the term. A compounded drug is "essentially a copy" if it has the same active ingredient in the same, similar, or easily substitutable strength, given by the same route [1][10].

The exception is narrow:

• The prescriber must document the difference. The prescription must show the specific change and the significant difference it makes for that patient. A patient name and a formulation alone are not enough [10].
• Price does not count. The guidance states that "other factors, such as a lower price, are not sufficient" [10].
• Small volume has a policy. FDA does not intend to take action if a compounder fills four or fewer prescriptions of such a product in a calendar month [1].
• Extra ingredients do not settle it. In FDA's own example, a semaglutide product with added vitamin B12 may still be essentially a copy. That applies when its strengths are within 10% of those of approved products [1].

Marketing claims have limits too. On February 6, 2026, FDA said companies cannot call compounded products generic versions or "the same as" approved drugs. They also cannot claim the same active ingredient or say the products are clinically proven [4].

These rules apply to compounders, prescribers, and marketers. This page explains FDA policy and is not legal advice.

Compounded Tirzepatide Timeline: Shortage, Court Case, and 2026 Crackdown

Compounded tirzepatide grew during a shortage that lasted from December 2022 to October 2024. Since then, FDA has ended the shortage grace periods, won in two federal courts, and moved against marketing claims and bulk compounding in 2026.

Sources: FDA declaratory order and compounding policy update, FDA statements and news releases, Fifth Circuit opinion No. 25-10600, Federal Register [1][3][4][5][6][7][8][9][26].

Why the Shortage Mattered

During a shortage, federal law lets compounders make copies of the scarce drug, as long as they meet the other conditions of sections 503A or 503B [11]. Once FDA declared the tirzepatide shortage resolved, that exemption ended, and the "essentially a copy" limits applied again [1].

FDA gave compounders time to wind down. Its December 2024 order set February 18, 2025 for pharmacies and March 19, 2025 for outsourcing facilities [1][3]. A February 2025 clarification extended each date to the court's injunction ruling if that came later. The ruling came on March 5, 2025, so the pharmacy period ended that day and the outsourcing facility period ended as planned on March 19 [1].

The Court Case

The case is Outsourcing Facilities Association v. FDA, No. 4:24-cv-00953, in the Northern District of Texas, with Eli Lilly on FDA's side. After the injunction denial, the district court granted summary judgment to FDA and Lilly, and the compounders appealed [9].

On August 27, 2026, a three-judge Fifth Circuit panel affirmed. The court found that FDA "engaged in reasoned decision-making" [9]. The opinion is unpublished, and a separate opinion covers the semaglutide case. As of September 24, 2026, we could not confirm whether further review has been requested, so treat the case as decided on appeal but not necessarily final.

What Changed in 2026

FDA shifted from shortage rules to enforcement in 2026. Three steps stand out:

• February 6. FDA announced its intent to take "decisive steps" to restrict GLP-1 active ingredients meant for non-FDA-approved compounded drugs that are mass-marketed as alternatives to approved drugs. It raised the possibility of seizure and injunction [4].
• March 3. FDA warned 30 telehealth companies, calling it the second group of letters to telehealth firms since the September 2025 crackdown began. The main violations were claims of sameness with approved products and branding that implied the telehealth firm made the drug [5].
• April 30. FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list, citing "no clinical need." The comment deadline was later extended to July 30, 2026 [6][7][8].

Since September 2025, an FDA green list import alert (66-80) has helped stop GLP-1 ingredients with potential quality concerns from entering the U.S., while ingredients from facilities FDA found compliant can still be imported [26]. FDA says it creates no new limits on legal compounding [2]. Semaglutide followed a similar path: its shortage ended on February 21, 2025, and its pharmacy and outsourcing grace periods ended on April 24 and May 22, 2025 [1].

Compounded Tirzepatide vs Zepbound and Mounjaro

Compounded tirzepatide is not the same as Zepbound or Mounjaro. The ingredient name may match, but the compounded product has no FDA approval, no FDA-reviewed label, and a different quality oversight path, and we found no published trials of compounded products [1][2][5].

Approved tirzepatide comes in set devices, each with step-by-step Instructions for Use [16]. Our page on Zepbound injection sites compares the pen, KwikPen, and vials. The multi-dose pen has its own Zepbound KwikPen guide.

Does compounded tirzepatide work? The weight loss results you read about come from trials of Lilly's product. We found no published randomized trial of a compounded tirzepatide product in a PubMed search in September 2026. A 2026 pharmacy journal editorial reviewed 33 compounded semaglutide and tirzepatide products and concluded that their efficacy and safety are "largely unknown" [22].

The approved products also have defined uses. Zepbound is approved, together with a reduced-calorie diet and increased physical activity, for weight reduction and long-term maintenance in adults with obesity, or with overweight and at least one weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity [16]. Mounjaro is a type 2 diabetes medicine, and its label lists each of its approved uses [18]. Our Zepbound vs Mounjaro comparison explains how the two brands differ.

Is Compounded Tirzepatide Safe? What FDA Reports Show

Compounded tirzepatide carries risks that approved products do not, because FDA does not check each product before it reaches patients. FDA had received more than 730 adverse event reports associated with compounded tirzepatide as of May 31, 2026, and says the real number is likely higher [2].

Adverse Event Reports

FDA also counts 990 reports for compounded semaglutide over the same period. It gives three caveats [2]:

• Underreporting. State-licensed pharmacies that are not outsourcing facilities do not have to report adverse events under federal law.
• Familiar problems. Many reported events look like the known side effects of the approved versions.
• Unclear cause. FDA says it is not always possible to tell whether the drug caused the event.

A 2025 study of FDA's adverse event database looked deeper. From 2018 to 2024, 707 of 81,078 GLP-1 reports involved compounded products. Compared with other GLP-1 reports, they had about 49 times the reporting odds for preparation errors, 19 times for contamination, and 2.35 times for hospitalization [20]. The estimates were imprecise: for preparation errors, the range ran from about 13 to 190 times.

The same study also found higher reporting odds for some digestive symptoms, suicidality, and gallbladder inflammation, and lower odds for administration and dosing errors [20]. It pooled liraglutide, semaglutide, and tirzepatide. Reporting odds show patterns in reports, not how often problems happen or what caused them.

Dosing Errors and Doses Beyond the Label

FDA has received reports of patients given compounded semaglutide or tirzepatide at doses beyond the FDA-approved label: more medicine per dose, more frequent doses, or faster dose increases. Reported symptoms included nausea, vomiting, diarrhea, abdominal pain, and constipation, and some cases were serious [2]. Our page on microdosing tirzepatide covers what the evidence says about doses below the label. For semaglutide, see our page on microdosing GLP-1.

Vials add a separate risk. In a 2024 alert about compounded semaglutide, FDA described mix-ups between milliliters, milligrams, and "units," varying concentrations, and syringes larger than the dose. Some patients took 5 to 20 times the intended dose, and some were hospitalized [13].

Think you took too much tirzepatide? The Zepbound Medication Guide says to call your healthcare provider or Poison Help at 1-800-222-1222, or go to the nearest emergency room right away [17]. Tirzepatide has a half-life of about 5 days, according to the label, so effects can last [16].

FDA also recommends these handling steps for compounded GLP-1 vials [2]:

• Throw away a multi-dose vial within 28 days after first use, even if medicine remains and even if the compounder says it lasts longer.
• Use a new sterile needle and syringe for every dose.
• Do not use an injectable GLP-1 that arrives warm or without enough refrigeration.

Added Ingredients and Fake Products

A 2026 editorial reviewed 33 compounded semaglutide and tirzepatide products sold online in early 2025 that differed from the approved versions (about one third contained tirzepatide). Of these, 48% combined the GLP-1 with ingredients such as vitamin B12 (cyanocobalamin), glycine, niacinamide, docusate, or ondansetron [22]. The authors saw "little justification" for adding nutrients or docusate, and only 18% of the products listed a beyond-use date and storage information.

A 2026 lab study reported a previously unidentified impurity in compounded tirzepatide mixed with certain forms of B12. It formed from a reaction between the two ingredients, and its clinical effects are unknown [21]. All five authors work for Eli Lilly, the maker of Zepbound and Mounjaro, so weigh the finding with that conflict in mind.

Fake and illegally sold products are a separate risk from pharmacy compounding. FDA says it knows of fraudulent compounded semaglutide and tirzepatide. Some labels name pharmacies that do not exist, and others name real, licensed pharmacies that did not make the product [2]. FDA also knows of one adverse event report associated with a product labeled as compounded tirzepatide from a pharmacy that did not actually make it, with redness, swelling, pain, and a red lump at the injection site [2].

FDA has also sent warning letters to companies selling tirzepatide and similar drugs labeled "for research purposes" or "not for human consumption" [2].

FDA warns that counterfeit and illegally sold online products may contain the wrong ingredients, too little or too much active ingredient, or none at all [2]. Retatrutide, an experimental drug, is not approved, and FDA says it cannot be used in compounding under federal law [2]. Read what published trials report in retatrutide side effects. Over-the-counter "GLP-1" supplements are a separate category; read GLP-1 supplements. Stick-on "GLP-1 patches" sold online are a different product again: they list no GLP-1 drug at all, as explained in do GLP-1 patches work.

How to Check That a Compounding Pharmacy Is Licensed

You can check the pharmacy behind a compounded tirzepatide prescription in a few minutes with free public tools. FDA's BeSafeRx page links to every state board of pharmacy lookup, and FDA publishes a weekly-updated list of registered outsourcing facilities [14][15].

Follow these steps:

1. Look up the pharmacy with your state board of pharmacy. Use the state links on FDA's BeSafeRx page. FDA says that if a pharmacy is not listed, "you should not use that pharmacy" [14].
2. Confirm the basics. A legitimate pharmacy requires a valid prescription, lists a US street address and phone number, and has a licensed pharmacist to answer questions [14].
3. Check outsourcing facilities with FDA. FDA's Registered Outsourcing Facilities table on fda.gov (updated September 8, 2026) shows inspection dates, Form 483 findings, recalls, and actions [15]. Use it to verify, not to shop. Under current FDA policy, outsourcing facilities cannot compound tirzepatide from bulk ingredients or copy Zepbound or Mounjaro [1]. Ask your prescriber about any tirzepatide product labeled as coming from one.
4. Match the label to the pharmacy. Because FDA has found fake labels, contact the pharmacy named on the label if anything looks wrong [2].
5. Watch for FDA's red flags. These are listed below.

FDA's red flags for compounded GLP-1 products include [2]:

• Claims that the product is the same as an FDA-approved drug
• Deep discounts
• A product that looks different, arrives damaged, or comes without instructions
• No health screening or no prescription from a licensed clinician
• No licensed clinician available for questions
• Spelling errors or a wrong pharmacy address on the label

Checking matters. A 2026 secret-shopper study in West Virginia and Oklahoma traced compounded GLP-1 products from 75 clinics and med spas to their supplier facilities. Of 21 supplier facilities checked, 4 (19%) were not licensed for sterile compounding, and 3 of 22 had faced state disciplinary action since 2023 [23].

Keep in mind that a licensed pharmacy does not make the product FDA approved. To report a problem, use FDA's MedWatch program online or by fax at 1-800-FDA-0178 [2].

If You Use Compounded Tirzepatide Now: Questions for Your Prescriber

If you use compounded tirzepatide, do not switch products or convert doses on your own; bring the product and its label to your prescriber. FDA's position is that compounded drugs belong only where an approved drug cannot meet a patient's needs [2].

Safety instructions still apply. The Zepbound Medication Guide says to stop and get medical help right away if you have signs of a serious allergic reaction. It also says to stop and call your healthcare provider right away if you have severe stomach pain that will not go away [17]. Do not use a vial that arrived warm [2]. If it looks different from what you received before, FDA lists that as a red flag, so contact the pharmacy and your prescriber before using it.

Questions worth asking:

• What is in my product? Ask about every ingredient, the concentration, and which pharmacy or outsourcing facility made it.
• Why compounded? Ask whether your prescription documents a significant difference that an approved product cannot provide.
• Would an approved option fit? Zepbound and Mounjaro each have FDA-approved uses, described in the comparison section above.
• How would switching work? The approved dose schedule is in each label, and your prescriber decides where you start. Our tirzepatide dosage chart summarizes the Zepbound and Mounjaro label schedules. The Zepbound label says it should not be used with other tirzepatide-containing products or any other GLP-1 medicine, so ask how to avoid overlap [16][17]. This page gives no dose conversions.
• How do I store and handle it? FDA advises discarding multi-dose vials within 28 days after first use [2].
• What will it cost? Ask your prescriber and insurer about coverage and any manufacturer programs for approved products. Our Zepbound coupon guide explains Lilly's savings programs for the approved product. Our page on what insurance covers Zepbound explains coverage rules.

Eating Well on Any Tirzepatide Treatment

Good nutrition matters on any tirzepatide treatment because appetite often drops and part of the weight lost is lean mass, which includes muscle. In a SURMOUNT-1 body composition substudy of 160 people, about a quarter of the weight lost with tirzepatide was lean mass, the same share as with placebo [24].

That is why protein and strength training matter during weight loss. A 2025 joint nutrition advisory notes that targets of 1.2 to 1.6 grams of protein per kilogram of body weight per day have been proposed during active weight loss [25]. The right body weight to use is unsettled, and strength training is also needed to protect muscle.

Practical habits help when you feel full fast:

• Eat the protein part of each meal first.
• Plan smaller meals and snacks built around protein foods.
• Add resistance exercise on most weeks, as your clinician advises.

If you want high-protein recipes and meal ideas sized for a smaller appetite, see our GLP-1 meal plan and protein guide.

Key Takeaways

• Not approved, not generic. Compounded tirzepatide has no FDA approval, and Mounjaro and Zepbound are the only approved tirzepatide products.
• The shortage is over. FDA resolved it in 2024, the grace periods ended in March 2025, and the Fifth Circuit upheld the ruling for FDA in August 2026.
• Only narrow compounding remains. Pharmacies may compound for an individual patient with a prescription. Copies of Zepbound or Mounjaro need the prescriber to document a significant difference for that patient. FDA has proposed closing the bulk route for outsourcing facilities.
• Safety gaps are real. FDA has more than 730 reports associated with compounded tirzepatide, plus dosing errors, added ingredients, and fake labels. If you think you took too much, call your provider or Poison Help at 1-800-222-1222, or go to the nearest emergency room right away.
• Verify before you trust. Check any pharmacy with your state board of pharmacy, and bring your questions to your prescriber.

Compounded tirzepatide rules keep changing, so this page reflects FDA and court records as of September 24, 2026.

Frequently Asked Questions

Is compounded tirzepatide banned?

Not completely. As of September 24, 2026, a state-licensed pharmacy may still compound tirzepatide for an individual patient with a prescription. Routine copies of Zepbound or Mounjaro are not allowed, and outsourcing facilities cannot compound it from bulk ingredients.

Is compounded tirzepatide the same as Zepbound?

No. It may contain the same named ingredient, but it is not FDA approved, has no FDA-reviewed label, and we found no published randomized trial of a compounded tirzepatide product. FDA says companies may not claim compounded products are the same as approved drugs.

Is compounded tirzepatide FDA approved?

No. FDA does not approve compounded drugs. The only FDA-approved tirzepatide products are Mounjaro and Zepbound.

Does compounded tirzepatide work as well as Zepbound or Mounjaro?

Nobody knows. The trials behind tirzepatide used the manufacturer's product, and we found no published randomized trial of a compounded tirzepatide product.

Is compounded tirzepatide going away?

Large-scale copies already ended in March 2025. FDA proposed in April 2026 to exclude tirzepatide from the 503B bulks list, and no final decision had been published as of September 24, 2026.

Why do some compounded tirzepatide products contain B12?

Some compounders add B12 or other ingredients and market the result as personalized. FDA's own example says a semaglutide product with added B12 may still count as essentially a copy of approved products. A 2026 lab study by Eli Lilly scientists reported an impurity in some tirzepatide and B12 mixtures, with unknown clinical effects.

Can a 503B outsourcing facility still make compounded tirzepatide?

Not from bulk ingredients and not as a copy of Zepbound or Mounjaro, according to FDA. Tirzepatide is on neither the 503B bulks list nor the shortage list, and FDA has proposed excluding it from the bulks list.

What should I do if my compounded tirzepatide arrives warm?

Do not use it. FDA advises against using any injectable GLP-1 drug that arrives warm or without enough refrigeration. Contact the pharmacy and your prescriber.

References

1. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, content current as of 04/01/2026: U.S. Food and Drug Administration
2. FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 09/01/2026: U.S. Food and Drug Administration
3. Declaratory order: resolution of shortages of tirzepatide injection products (Mounjaro and Zepbound), December 19, 2024: U.S. Food and Drug Administration
4. FDA intends to take action against non-FDA-approved GLP-1 drugs, February 6, 2026: U.S. Food and Drug Administration
5. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s, March 3, 2026: U.S. Food and Drug Administration
6. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list, April 30, 2026: U.S. Food and Drug Administration
7. List of bulk drug substances for which there is a clinical need under section 503B, 91 FR 23431, May 1, 2026: Federal Register
8. Extension of comment period, 91 FR 38719, June 26, 2026: Federal Register
9. Outsourcing Facilities Association v. FDA, No. 25-10600, filed August 27, 2026: U.S. Court of Appeals for the Fifth Circuit
10. Compounded drug products that are essentially copies of a commercially available drug product under section 503A, guidance for industry, January 2018: U.S. Food and Drug Administration
11. Compounding and the FDA: questions and answers: U.S. Food and Drug Administration
12. Human drug compounding laws: U.S. Food and Drug Administration
13. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, 2024: U.S. Food and Drug Administration
14. BeSafeRx: locate a state-licensed online pharmacy: U.S. Food and Drug Administration
15. Registered outsourcing facilities, updated September 8, 2026: U.S. Food and Drug Administration
16. Zepbound (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
17. Zepbound Medication Guide, revised 08/2026: Eli Lilly
18. Mounjaro (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
19. Drugs@FDA data for tirzepatide, openFDA: U.S. Food and Drug Administration
20. McCall KL et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf. Published online April 2025; 25(3):581-588
21. Jordan B et al. A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. Expert Opin Drug Saf, 2026
22. Belcourt J et al. Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Ann Pharmacother, 2026
23. DiStefano MJ et al. Postshortage compounded GLP-1 RA market in 2 states with potentially high demand. JAMA Health Forum, 2026
24. Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab, 2025
25. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA, and TOS, 2025
26. FDA launches green list to protect Americans from illegal imported GLP-1 drug ingredients, September 5, 2025: U.S. Food and Drug Administration

This article is for education only and is not medical or legal advice. It summarizes FDA records, court records, the FDA label, and published research, and it gives no personalized dosing advice. Talk to your prescriber about your treatment and your dose. Read our full medical disclaimer.